Changes in the Prescription of Glucose‐Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study
Open Access
- 16 July 2019
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (14) , e012244
Abstract
Background: Evidence accumulated that some glucose‐lowering medications protect against cardiovascular events ( CVEs ) in patients with type 2 diabetes mellitus (T2DM) and established cardiovascular disease. The present study evaluated if and how glucose‐lowering medication prescription pattern changes in T2DM after a CVE. Methods and Results: DATAFILE (Diabetes Therapy After a Cardiovascular Event) was a retrospective multicenter study conducted at 12 diabetes mellitus specialist outpatient clinics in Italy. We identified T2DM patients with an incident CVE for whom a follow‐up visit was available after the event. We selected control T2DM patients without an incident CVE , who were matched with cases for age, sex, known diabetes mellitus duration, baseline hemoglobin A 1c , kidney function, and follow‐up time. We extracted clinical variables and compared prescribed therapies at baseline and follow‐up. We included 563 patients with and 497 matched patients without an incident CVE . As expected, patients with a subsequent CVE had a higher baseline prevalence of ischemic heart disease. After a median of 9.5 months, in patients with versus those without a CVE , there was a significant increase in the prescription of beta‐blockers, loop diuretics, dual antiplatelet therapy, and, among glucose‐lowering medications, a significant decrease in metformin. Hemoglobin A 1c marginally declined only in the control group, whereas low‐density lipoprotein cholesterol decreased only in patients with CVE . Conclusions: This study highlights that occurrence of a CVE in T2DM patients did not prime the prescription of glucose‐lowering medications provided with cardiovascular protective effects, even though glucose control remained poor. These data emphasize the need to optimize the therapeutic regimen of T2DM patients with established cardiovascular disease, according to updated guidelines.Keywords
This publication has 34 references indexed in Scilit:
- Cardiovascular Actions of Incretin-Based TherapiesCirculation Research, 2014
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes MellitusNew England Journal of Medicine, 2013
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 DiabetesNew England Journal of Medicine, 2013
- Sulphonylureas and risk of cardiovascular disease: systematic review and meta‐analysisDiabetic Medicine, 2013
- Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes RegisterBMJ Open, 2012
- SGLT2 inhibition in diabetes mellitus: rationale and clinical prospectsNature Reviews Endocrinology, 2012
- Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1Vascular Pharmacology, 2011
- Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studiesBMJ, 2011
- Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research databaseBMJ, 2009
- Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes MellitusJAMA, 2007